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Summary
 
It is currently well established that HIV-1 Vpr augments viral replication in primary human
macrophages. In its virion-associated form, Vpr has been suggested to aid efficient translocation
of the proviral DNA into the cell nucleus. Although Vpr growth-arrests dividing T cells, the
relevance of this biological activity in nondividing macrophages is unclear. Here we use Vpr-
mutants to demonstrate that the molecular determinants involved in G2-arresting T cells are
also involved in increasing viral transcription in macrophages, even though these cells are re-
fractive to the diploid DNA status typical of G2 phase. Our results suggest that the two pheno-
types, namely the nuclear localization and the G2-arrest activity of the protein, segregate func-
tionally among the late and early functions of Vpr. The nuclear localization property of Vpr
correlates with its ability to effectively target the proviral DNA to the cell nucleus early in the
infection, whereas the G2-arrest phenotype correlates with its ability to activate viral transcrip-
tion after establishment of an infection. These two functions may render Vpr’s role essential
and not accessory under infection conditions that closely mimic the in vivo situation, that is,
primary cells being infected at low viral inputs.
 
T
 
he Vpr protein is one of the regulatory gene products
coded by HIV-1, the etiological agent of AIDS, and is
expressed late in the infection cycle (1, 2). All primate len-
tiviruses including HIV-1 code for a Vpr-like product.
However, some lentiviruses such as HIV-2 and most sim-
ian immunodeficiency viruses (SIVs)
 
1
 
 code not only for
Vpr but also for a second protein named Vpx, which shares
considerable sequence homology with Vpr (3, 4). Pheno-
typically, several studies demonstrate that viruses that code
for a Vpr protein replicate to much higher levels in mac-
rophages than do their Vpr-negative counterparts (5–9).
However, exactly how the protein contributes to this effect
is not clearly understood.
The fact that Vpr is packaged in the progeny virions at
high copy numbers strongly suggests that the protein could
play a role early in the infection (10). Experimental support
for an early functional role comes from studies in which
Vpr contributed to the nuclear import of proviral DNA in
nondividing cells such as macrophages (11). In addition, a
late function is also suggested by experiments in which ex-
cluding the late de novo expression of Vpr effectively abol-
ished the augmented replication even though the protein
was made available in the virion early in the infection (7).
However, the ability of Vpr to target the proviral DNA to
the nuclear compartment early in the infection was not
monitored in this study, and therefore the authors could
not formally preclude an additional role for the protein
early in the infection (7).
Hence, several issues remain unclear about our under-
standing of the ability of Vpr to increase viral replication in
macrophages. Does Vpr play a role late in the viral life cy-
cle that can be segregated from its function early in the in-
fection, and if so, at what replication step does this late
function manifest itself? Given the fact that other virion-
associated proteins such as Gag matrix p17 (11, 12) and vi-
ral integrase (13) also appear to facilitate proviral nuclear
import, is Vpr’s nuclear targeting function essential? If not,
what is the relevance of evolutionary conservation of mul-
tiple nucleophilic determinants? If so, why has it not been
detected in earlier studies? Finally, is Vpr’s ability to
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growth-arrest proliferating cells (14–19) an effect confined
to cycling T-cells or does it have functional correlates in
nondividing macrophages that are refractive to cell-cycle
changes?
In this study we attempt to address these questions by
systematically monitoring the relative contribution by HIV-1
Vpr to the early and late viral replication events in primary
human macrophage cultures. We monitor the levels of
proviral DNA targeted to the cell-nucleus in the presence
and absence of Vpr, as well as the ensuing virus production
and the pattern of RNA expression at the single cell level
using in situ analysis. We also monitor the replication of
Vpr-mutants that lack either the protein’s ability to localize
to the nucleus or its ability to growth-arrest T cells in an
effort to gauge the relevance of these phenotypes during
macrophage infection.
 
Materials and Methods
 
Isolation and Culture of Peripheral Blood–derived Macrophages.
 
Blood units from HIV seronegative volunteers were obtained
from the Hôpital Maisonneuve Rosemont (Montreal, Canada).
PBMCs were isolated by Ficoll-Paque centrifugation as recom-
mended by the manufacturer (Pharmacia Biotech AB, Uppsala,
Sweden), washed thoroughly to remove contaminating platelets,
and cryopreserved. An enriched population of monocyte-derived
macrophages were first isolated by adherence to plastic as previ-
ously described (5). Further purification was achieved by negative
selection where the enriched macrophage population was incu-
bated with a cocktail of monoclonal antibodies against T and B
cells followed by subsequent depletion using a secondary anti-
body conjugated to magnetic beads (Dynal Inc., Lake Success,
NY) as previously described (20). Purified macrophages were
plated in 6-well plates at a concentration of 2.5 
 
3 
 
10
 
6
 
 cells per
well and maintained in endotoxin-free RPMI 1640 media (GIBCO
BRL, Gaithersburg, MD) containing 10% FCS, 
 
l
 
-glutamine,
penicillin (100 U/
 
m
 
l), streptomycin (100 U/
 
m
 
l), and gentamycin
(10 
 
m
 
g/ml). The resulting adherent macrophages were 
 
.
 
93%
positive by nonspecific esterase test (Sigma Chemical Co., St.
Louis, MO).
 
Proviral Constructs, Infections, and Replication Kinetics.
 
The pre-
viously well-characterized isogenic HxBRU based clones (21)
were rendered macrophage-tropic by transferring the SalI–
BamHI fragment from another well-characterized macrophage-
tropic construct ADA (NLHXADA-SM), provided by Dr. Lee
Ratner (University of Washington School of Medicine, St. Louis,
MO) (9). The construction of the HxBRU parental clones that
code for the wild-type Vpr or the Vpr-negative ATG
 
2
 
 mutant
(where the Vpr ATG initiation codon has been mutated to pre-
vent protein translation) have been previously described (21).
The R62P and R80A were subcloned in this background using a
two-step PCR-based method as previously described (21).
Cos-7 cells were plated at 8 
 
3 
 
10
 
5
 
 cells per 100-mm plate, cul-
tured overnight, and transfected with proviral constructs by cal-
cium phosphate method. To generate viral stocks, supernatants
were collected 72 h after transfection, concentrated by ultracen-
trifugation at 35,000 rpm for 2.5 h, filtered through 0.45-
 
m
 
m fil-
ters, treated with DNase (25 U/ml) to remove contaminating
plasmid DNA, and stored at 
 
2
 
80
 
8
 
C. In vitro differentiated mac-
rophages that had been in culture for 7 d were adsorbed with vi-
rus for 8 h at 37
 
8
 
C and were subsequently washed thoroughly to
remove free virus and were maintained in RPMI 1640 complete
medium containing 100 nM Palinavir (BioMega-Boehringer In-
gelheim, Laval, Quebec, Canada), a previously well characterized
protease inhibitor (22). Half of the medium was changed every
3–4 d with fresh media supplemented with 100 nM Palinavir. Vi-
rus production in cultures was determined by measuring superna-
tant p24 levels by standard ELISA techniques.
 
In Situ Hybridization.
 
For in situ hybridization purposes, pu-
rified macrophages were maintained after purification for 7 d in
Lab-Tech slides (Nunc
 
Ô
 
, Naperville, IL) and subsequently in-
fected at varying viral inputs under conditions similar to the ones
used for one-step replication studies in the presence of 100 nM
Palinavir. Hybridization procedures were performed using stan-
dard protocols (23, 24) using an antisense probe previously de-
scribed in detail (25). This probe contains a 92-bp sequence com-
plementary to the Sty-1 (nucleotide 7591) to HindIII (nucleotide
7683) fragment overlapping the HxBc2 envelope sequences
found in the ADA chimeric clones (9). Thus, the hybridization
procedure identified both full-length and singly spliced mRNAs,
both of which contain the target envelope sequences. Based on
earlier optimization procedures, RNA pattern was determined at
14 d after infection as all donors tested clearly showed the Vpr-
mediated phenotype of augmented replication by this time.
 
PCR Analysis and Southern Blotting.
 
Total DNA lysates were
prepared to monitor the efficiency of reverse transcription at different
time points early in the infection as previously described (26). Al-
ternatively, proviral levels found in the nuclear compartment
were monitored as previously described (26). PCR analysis to de-
tect HIV-1 proviral products was performed using the following
primers in the Gag sequence: sense oligonucleotide 5
 
9
 
-ATA
ATC CAC CTA TCC CAG TAG GAG AAA T-3
 
9
 
, and anti-
sense oligonucleotide 5
 
9
 
-TTT GGT CCT TGT CTT ATG
TCC AGA ATG C-3
 
9
 
. These primers amplified a fragment of
114 bp corresponding to the sequence 1090 to 1204 in the HxBRU
strain. Alternatively, the cellular 
 
b
 
2-adrenergic receptor (
 
b
 
2-AR)
gene sequences were detected using the following primers: sense
5
 
9
 
-TAG GCC TTC AAA GAA GAC CTC C-3
 
9
 
, and antisense
5
 
9
 
-CGT CTA CTC CAG GGT CTT TCA G-3
 
9
 
. PCR prod-
ucts from this amplification generated a 399-bp fragment that
corresponded to the sequence 1465 to 1821 of the human 
 
b
 
2-AR
gene. Amplification was performed using 
 
Taq
 
 DNA polymerase
(Perkin Elmer, Norwalk, CT) for 30 cycles of 1 min at 94
 
8
 
C, 2
min at 50
 
8
 
C, and 3 min at 72
 
8
 
C. 
 
a
 
-[
 
32
 
P]dATP-labeled probes ca-
pable of recognizing the PCR products were generated as fol-
lows: HIV-1 Gag probe was generated by nick translating with
 
a
 
-[
 
32
 
P]dATP (3,000 Ci/mmol; ICN Radiochemicals, Costa Mesa,
CA), the 591-bp ApaI to PstI digestion fragment corresponding to
positions 964 to 1555 in the HxBc2 provirus sequence. 
 
b
 
2-AR
probe was generated by similarly nick translating a fragment cor-
responding to the sequence 1465 to 1821 from a well character-
ized 
 
b
 
2-AR eukaryotic expressor construct (27).
 
Results
 
Correlation of the G2-arrest and Nuclear Localization Pheno-
types of Vpr with its Ability to Establish a Productive Infection in
Macrophages.
 
To explore what role, if any, Vpr-mediated
G2-arrest and nuclear localization played during viral repli-
cation in nondividing target cells such as macrophages, we
compared the replication of a virus that coded for a wild-
type Vpr or no Vpr at all (ATG
 
2
 
 mutant), to that of viruses
coding for mutations in the gene that selectively affected 
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either the G2-arrest or the nuclear localization activity of
the protein. For this purpose, the macrophage-tropic enve-
lope region from the well-characterized NLHX-ADA-SM
construct (9) was transferred into HIV-1 constructs that
coded either for the wild-type Vpr or for a mutated version
of the protein (21). The two mutations used in this study to
gauge how the G2-arrest and nuclear localization pheno-
types of Vpr contribute to HIV-1 replication in macrophages
were chosen based on previously published reports that clearly
separate these functions at the structural level (28, 29).The
R62P and R80A proviruses expressed, respectively, a Vpr-
mutant that substituted the Arginine residue at position 62
with a Proline and one that substituted the Arginine resi-
due at position 80 with an Alanine. The Proline substitu-
tion mutant, R62P, retained its ability to G2-arrest cells
but lost its ability to localize to the nucleus as it disrupted a
helical domain shown by earlier studies to affect the nuclear
localization phenotype specifically (29–32). The R80A
mutant was capable of localizing to the nucleus but was im-
paired in its ability to growth-arrest T cells, also as previ-
ously shown (28). These observations are in agreement
with a number of earlier functional studies that have char-
acterized central helical and COOH-terminal domains of
Vpr (21, 28, 29), and which are summarized in Table 1.
Whether or not Vpr is dispensable for viral replication in
macrophages has been controversial as there is limited con-
sensus on the extent to which the virus is impaired in the
absence of the protein. Reports from independent groups
have documented anywhere from 2-fold to close to 100-fold
impairment (5, 7, 9). As some investigators have suggested
that the viral input may contribute to the in vitro replica-
tion kinetics of viruses mutated in another nucleophilic de-
terminant, matrix p17 (33), as well as viruses mutated in
Nef, the accessory protein (34, 35), we tested if the input
multiplicity can compensate for the Vpr-mediated aug-
mentation of viral replication. To address this issue, we in-
fected purified macrophages kept in culture for 7 d with
the wild-type or Vpr-mutant viruses at either a high input
titer (50 ng) or one third serial dilutions thereof (16.7 ng,
5.6 ng, 1.85 ng, 619 pg). One-step replication was ensured
by maintaining the infected cultures in the presence of the
potent protease inhibitor Palinavir (BioMega-Boehringer
Ingelheim), which effectively prevented multiple rounds of
infection from newly generated viruses in this system (data
not shown). We have previously shown that treatment
with this inhibitor results in the release of noninfectious
particles into the supernatant due to a block at the virion
maturation step (22). This culture system allowed us to look
at a one-step viral replication without the complication of
the progression of viral infection through the culture.
Our data suggests that at low viral inputs both the ability
of the protein to localize to the nucleus and its ability to
G2-arrest dividing cells appeared to be essential for in-
creased viral replication in macrophages. The wild-type
protein capable of both activities established a readily ap-
parent infection even at the lowest multiplicity tested (Fig.
1). However, the R62P mutant, which lacks the nuclear
localization activity, and the R80A mutant, which lacks the
G2-arrest phenotype (Table 1) are both impaired at low vi-
ral inputs (Fig. 1). The ATG
 
2
 
 mutant, which lacks both
these biological activities, is clearly impaired at the low
multiplicities tested (Fig. 1).
However, at high viral inputs, the requirement for the
nuclear localization is no longer essential for augmented
replication, whereas the G2-arrest ability is still required.
Note that the R80A mutant that lacks the G2-arrest activ-
ity shows impairment of replication at the high viral inputs
even though it is capable of localizing to the nucleus,
whereas the R62P mutant possessing the G2-arrest activity
is rescued even though it fails to localize to the nucleus
(Fig. 1).
 
Ability of the Wild-type and Mutant Vpr Proteins to Target
Proviral DNA to the Nuclear Compartment.
 
We sought to
understand if either the nuclear localization or the G2-
arrest activity associated with Vpr affected the protein’s
ability to target the proviral DNA to the nuclear compart-
ment. To formally address this issue, we used a semiquanti-
tative PCR approach to monitor the total levels of HIV-1
proviral generation and the levels of provirus found in the
nuclear compartment at various time points after addition
of the initial viral inoculum as previously described (26).
Single-step viral replication conditions identical to the ones
used to monitor productive infection by p24 were used for
this purpose. The total proviral synthesis was approximately
the same both in the presence and absence of Vpr, indicat-
ing that neither viral entry nor reverse transcription was
radically affected by the protein (data not shown), an obser-
vation that is in agreement with previous reports (11, 12).
However, absence of Vpr drastically reduced the targeting
of the proviral DNA to the nuclear compartment and this
effect, interestingly, only became apparent at low viral in-
puts (Fig. 2, 
 
A
 
 and 
 
B
 
, 1.85- and 0.619-ng lanes). It is also
clear that the drastic impairment in nuclear targeting is not
due to a temporal delay in transport, as nuclear proviral lev-
els remain constant after 72 h (Fig. 2 
 
A
 
). However, at high
viral inputs the PCR data clearly demonstrates that the
proviral import function proceeds efficiently in spite of the
absence of Vpr (ATG
 
2
 
), or its inability to localize to the
nucleus (R62P) (Fig. 2 
 
B
 
). This is probably due to comple-
mentation of the nuclear import function at high viral in-
puts by the viral integrase protein (13) and the Gag matrix
 
Table 1.
 
Nuclear Localization and G2-arrest Phenotypes of 
Various Vpr Genes
 
Vpr gene Wild-type ATG
 
2
 
R62P R80A
G2-arrest Ability Positive Negative Positive Negative
Subcellular Nuclear N/A
 
*
 
Cytoplasmic Nuclear
localization
Summary of G2 arrest and nuclear localization phenotypes associated
with the wild-type and mutant Vpr-expressing viruses.
 
*
 
The ATG
 
2
 
 mutant involved elimination of the Vpr initiation codon
and hence did not translate a Vpr product as previously described (21). 
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p17 product (11, 12, 36). Note, however, that at lower vi-
ral inputs Vpr was essential for efficient nuclear targeting of
the provirus regardless of the presence of these comple-
mentary viral nucleophilic factors (Fig. 2 
 
B
 
, compare the
1.85-ng lanes). Also, note that at lower viral inputs, inabil-
ity of Vpr to localize to the nucleus impairs its ability to tar-
get the proviral DNA to the nuclear compartment (com-
pare the 1.85-ng lanes of R62P to that of wild-type).
However, an additional contribution to the augmented
replication is provided by the protein’s G2-arrest ability, as
similar nuclear levels of proviral DNA present at higher vi-
ral inputs (Fig. 2, compare the 50-ng lanes), still lead to a
nonproductive infection in the R80A and ATG
 
2
 
 cultures
(Fig. 1). This clearly suggests that access to the nucleus by
itself is not sufficient to ensure productive infection, and
that G2-arrest ability is essential to induce productive infec-
tion after achieving efficient proviral nuclear targeting. This
conclusion is underscored by the productive infection of
R62P mutation once efficient targeting of its proviral DNA
is achieved by the use of high viral titers (Fig. 1). 
 
RNA Expression Pattern Among Cultures Infected with Wild-
Type and Vpr-Mutant Viruses. 
 
Though analysis of replica-
tion kinetics by monitoring supernatant p24 levels allowed
us to gauge productive infection, this did not clarify if the
highly reduced viral production apparent in some cultures
(Fig. 1, ATG
 
2
 
 and R80A) is due to a reduction in the
Figure 2. Levels of HIV-1 DNA found in the nuclear compartment among viruses expressing the wild-type and mutant Vpr proteins. (A) Kinetics of
proviral DNA detection in the nuclear compartment for wild-type and Vpr negative mutants at a nonsaturating viral input (1.85 ng). HIV Gag sequences
found targeted to the nucleus reached a plateau by day 3 and remained constant, indicating that multiple rounds of infection in the presence of the pro-
tease inhibitor does not occur in this system. (B) HIV-1 proviral detection in the nuclear compartment at day 14 after infection at various viral inputs for
the wild-type, ATG2, R62P, and R80A mutants. Similar levels of cellular DNA were analyzed as indicated by the b2-AR detection. Standards for HIV-Gag
detection were measured by diluting uninfected macrophages with a known number of chronically infected ACH-2 cells (48).
Figure 1. Single cycle replica-
tion kinetics of viruses expressing
the wild-type and mutant Vpr
proteins in primary human mac-
rophages. Peripheral blood
monocyte–derived macrophages
cultured for 7 d were infected
with increasing viral inputs rang-
ing from 619 pg to 50 ng (repre-
sented in the horizontal axis).
Viral production after infection
was monitored at regular inter-
vals by measuring p24 levels in
the culture supernatants (repre-
sented in the vertical axis as p24
ng/ml). The lateral axis represents
days after infection spanning the
peak of viral replication. Inde-
pendent experiments performed
with different donors and viral
stocks consistently showed simi-
lar kinetics. 
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number of infected cells, or, alternatively, due to the same
number of infected cells producing lower amounts of vi-
ruses per cell. For example, it is conceivable that a subpop-
ulation of macrophages are susceptible to HIV-1 infection
in the absence of Vpr, whereas others are not. This is a pos-
sibility that needs to be considered as it is clear that blood-
derived macrophages are a heterogeneous population of
cells. Also, it is conceivable that infection itself is estab-
lished in a small fraction of proliferating cells as previously
suggested (37). Hence, in theory, the saturation seen in the
p24 assay (Fig. 1) may result from saturation of this subpop-
ulation, after which increasing the viral input results in no
further infection as there are no further susceptible cells.
To explore the issue we performed in situ hybridization
in lab-tech slides under conditions identical to the ones
used to monitor viral replication by p24 and proviral DNA
targeting to the nucleus (Fig. 3). Hybridization procedures
were performed according to standard protocols (23, 24) using
an antisense probe previously described in detail (25). This
probe identified both full length and singly spliced mRNAs
in HIV-1 infected primary cells (20). We chose to look at
two input titers in this experiment, one at the higher satu-
rating level (50 ng) and another at the lower end (1.85 ng).
Note that the in situ evidence clearly suggests that Vpr
upregulates transcription in these nondividing cells, an ef-
fect linked to its ability to induce G2-arrest: mutants lack-
ing the Vpr-G2-arrest capability (ATG
 
2
 
 and R80A) clearly
show drastic reduction in productively infected cells, even
though the total number of infected cells were similar (in
the range of 90%) at high viral inputs (Fig. 3 
 
c
 
 and 
 
e
 
, and
Table 2). Interestingly, as exemplified by the R62P muta-
tion at low viral inputs, the lack of nuclear targeting takes
precedence over the ability to increase transcription as lack
of proviral nuclear targeting impedes the establishment of
infection (Fig. 2 
 
B
 
, and Table 2). However, the importance
of this late transcriptional role is underscored by the lack of
productive infection in the R80A mutant where close to
wild-type levels of nuclear import occurs (Table 2). Also,
the Vpr-negative ATG mutant still fails to show productive
infection (Fig. 1 and Table 2) even after effective targeting
of its proviral DNA to the nuclear compartment at high vi-
ral inputs (Fig. 2 
 
B
 
, 50-ng lane).
Also, both the wild-type and R62P cultures (both of
which growth-arrest proliferating cells in the G2 phase)
failed to change the DNA profile of these terminally differ-
entiated macrophages, as expected. Both the uninfected
and infected cultures showed 
 
,
 
1% of the cells in the G2
phase of the cell-cycle (data not shown) even though in the
range of 90% of the cells were shown to be infected (Table
2). Hence, the observed correlation between G2-arrest ac-
tivity and the increased replication in macrophages is likely
Figure 3. Productive and silent
infection patterns associated with
wild-type and Vpr-mutant cultures
as assessed by in situ hybridization.
Panels depict in situ patterns found
in macrophage cultures infected on
day 7 after isolation with high viral
titers (50 ng) and monitored for
RNA expression at 2 wk after in-
fection, when a clear difference in
virion production was evident as
assessed by supernatant p24 levels (see Fig. 1). Uninfected culture (a),
wild-type (b), ATG2 (c), R62P (d), and R80A (e).
 
Table 2.
 
Pattern of RNA Expression among HIV-1 Infected Primary Human Macrophage Cultures
 
Vpr gene ATG
 
2
 
Wild-type R62P R80A
Viral inoculum
 
*
 
High Low High Low High Low High Low
Total number of positive cells
 
‡
 
91.0% 6.5% 89.5% 67.5% 94.5% 8.0% 93.5% 42.5%
Productively infected cells
 
§
 
2.5% 0.0% 43.5% 29.0% 39.0% 3.0% 4.5% 1.5%
RNA expression pattern as assessed by in situ hybridization.
 
*
 
High signifies 50 ng of viral input and low signifies 1.85 ng of viral input as assessed by p24 ELISA.
 
‡
 
Positivity is defined as cells expressing 
 
.
 
20 grains over background levels.
 
§
 
Productive infection is defined as the proportion of cells expressing 100 grains or more over background levels. Consistent results were also ob-
tained from macrophages derived from a second donor with independent viral stocks. A minimum of 200 cells were quantified using methods we
have previously described (20). 
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due to biochemical events rather than actual DNA duplica-
tion that characterize the G2-arrest status in proliferating T
cells.
 
Discussion
 
Current consensus suggests that HIV-1 Vpr mediates
two biological activities in target cells. One activity has
been described for nondividing and quiescent cells, such as
macrophages, where Vpr targets the HIV-1 proviral DNA
to the cell’s nucleus even in the absence of mitosis (38).
The second function has been described in T cells, where
Vpr induced growth arrest in the G2-phase of the cell cy-
cle. Most prototypic retroviruses fail to infect nondividing
cells, as mitosis and, conceivably, the nuclear membrane
disintegration that occurs during cell-division are prerequi-
sites to their gaining access to the cell-nucleus. However,
Vpr, and at least two other HIV-1 virion proteins, matrix
p17 (11, 12, 36) and integrase (13), have been known to
ensure effective targeting of proviral DNA to the nuclear
compartment. This leaves open the question why HIV-1
codes for apparently redundant nuclear targeting determi-
nants.
The data presented here suggests that Vpr’s contribution
to proviral nuclear targeting is an essential rather than an
accessory function under conditions that closely mimic in
vivo situations, that is, primary cells being infected at low
viral inputs. At low viral inputs, lack of Vpr results in the
lack of infection, a function not mitigated by the presence
of other nucleophilic determinants such as Gag matrix p17
or viral integrase (11–13, 36, 39). This also provides sup-
port to the evolutionary conservation of multiple, and ap-
parently redundant, nucleophilic determinants in HIV. It is
conceivable that optimal nuclear targeting occurs due to
the interdependent nature of these multiple determinants.
This may be due to the multivalent nature of the interac-
tion of the preintegration complex with cellular targets.
We assume that the lack of even one such valancy could
reduce the chance of effective targeting, especially under
restrictive conditions such as low viral inputs. These results
underscore the importance of using low multiplicity in in
vitro studies and provides support to previous suggestions
that higher multiplicities of infection may mask certain bio-
logical activities in vitro
 
 
 
(33).
Mechanistically, data presented here directly link the
ability of Vpr to localize to the nucleus with that of its abil-
ity to target the provirus to the cellular genome at low
multiplicities. This is illustrated by the notable reduction in
proviral targeting at low viral inputs associated with mu-
tants that either fail to code for a Vpr product (ATG
 
2
 
), or
alternatively, code for a Vpr protein (R62P) incapable of
reaching the nucleus (Fig. 2 B). The R80A mutant that is
capable of reaching the nucleus, performs the proviral tar-
geting function at levels comparable to its nuclear localiza-
tion abilities (Table 1). It is unlikely that the failure to de-
tect viral replication in some cases is due to alterations
elsewhere in the genome as all viruses used in this study es-
tablished a readily apparent replication in proliferating T
cells (data not shown).
In this study we also provide direct evidence suggesting
that HIV-1 Vpr upregulates transcription in infected mac-
rophages. A late function for Vpr has been suggested by an
earlier study (7) and our work provides formal proof for a
late Vpr function independent of its nuclear targeting abil-
ity. Note that at high viral inputs, where a vast majority of
cells are infected (in the range of 90%) in both the wild-
type and Vpr-negative (ATG2) cultures, the wild-type Vpr
expressing viruses generate higher levels of HIV-1 mRNA
than the ATG-mutant (Fig. 3). We also demonstrate that
the G2-arrest activity of Vpr, first identified in proliferating
T cells, correlates with this increased transcriptional activity
in macrophages. As macrophages are refractive to actual
proliferation, it is conceivable that Vpr induces biochemical
changes in macrophages, which in the context of the divid-
ing cells leads to cell cycle arrest. Clearly, further studies are
needed to understand the changes brought about by Vpr in
the macrophage’s cellular milieu.
Our results demonstrating a transcriptional role for Vpr
in a relevant target cell provides biological relevance to a
number of biochemical observations made earlier. We have
previously shown that Vpr can increase reporter gene activ-
ity from variety of viral promoters (10). In fact, extracellu-
lar Vpr has been shown to induce latently infected cells
into productive expression, again suggesting a role for the
protein after integration (40, 41). It has also been shown
that preventing the late expression of Vpr by using anti-
sense approaches drastically reduces viral replication (6). It
is interesting in this regard that a recent report suggests that
Vpr can modulate the NFkB pathway by upregulating IkB
transcription (42).
Hence, there appears to be a clearly identifiable func-
tional contribution to both early and late viral replication
events by HIV-1 Vpr and the results presented here
strongly suggest that the notable augmentation in the viral
production seen in the presence of Vpr at low viral inputs is
probably due to the additive contributions of both the early
and late functions of the protein. In in vitro experiments, it
may not be possible to demonstrate the early and late func-
tions in exclusion of each other except by using specific
mutants or physiologically relevant viral inputs, and this
could explain why some early studies vastly underestimated
Vpr’s contribution to viral replication. It is conceivable that
similar mutants favoring one or the other function may be
favored in some stages of the disease in vivo. For instance,
in vitro studies show that mutating the COOH-terminal
region primarily impairs the G2-arrest function of the pro-
tein (28, 29), and in this study we correlate this activity
with increased viral replication. In this regard, it is interest-
ing to note that such COOH-terminal mutations are asso-
ciated with low viral loads and lack of disease progression
in vivo (43). In fact, Vpr’s combined ability to confer opti-
mal infectivity (early function) and its ability to augment
viral production after such infection (late function) may
provide a considerable selective advantage in vivo to vi-1109 Subbramanian et al.
ruses that code for this protein. This notion is strongly sup-
ported by the fact that HIV-2 and SIV conserve both Vpx
and Vpr-2, two separate proteins amongst which the two
functions of HIV-1 Vpr segregate (44).
Some of the regulatory products coded for by HIV-1
have been deemed dispensable or “accessory” based on the
fact that viral replication in vitro, albeit attenuated, still oc-
curs even in their absence (45). However, several lines of
evidence suggest that accessory genes are not likely to be
dispensable in vivo. The ability to code for these genes is
maintained in distant lentiviral relatives and specifically
within the HIV-1 family of viruses. The open reading
frames are invariably retained in all HIV-1 clades and nota-
ble conservation of the gene sequences is a common fea-
ture. It is particularly difficult to reconcile such conserva-
tion of nonessential genes in a highly adaptable system such
as HIV-1. In this context, it is interesting to note that some
experiments have documented repair or recombinational
mechanisms that reestablish the expression of Vpr protein
in vivo, suggesting a functional need for this protein during
natural infection (46, 47). The potential in vivo relevance
of accessory proteins such as Vpr is also suggested by some
in vitro experiments in which the inability to code for
these proteins appears to affect HIV-1 replication acutely
when primary rather than transformed cells are used as tar-
gets (for review see reference 45). This observation again
suggests experimental conditions more representative of an
in vivo milieu may be necessary to truly assess the func-
tional relevance of these genes. Our results suggest that one
such accessory protein, HIV-1 Vpr, plays an essential and
not a dispensable role in the infection of nondividing cells
under conditions that closely mimic in vivo situations, that
is, primary cells being infected at low viral inputs.
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